MedinCell S.A. MEDCL.PA Stock
MedinCell S.A. Price Chart
MedinCell S.A. MEDCL.PA Financial and Trading Overview
| MedinCell S.A. stock price | 9.17 EUR |
| Previous Close | 6.92 EUR |
| Open | 6.96 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 6.96 - 7.19 EUR |
| 52 Week Range | 4.73 - 10.5 EUR |
| Volume | 83.04K EUR |
| Avg. Volume | 81.87K EUR |
| Market Cap | 205.52M EUR |
| Beta (5Y Monthly) | 1.063009 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.01 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.7 EUR |
MEDCL.PA Valuation Measures
| Enterprise Value | 204.24M EUR |
| Trailing P/E | N/A |
| Forward P/E | -14.387755 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.133667 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 23.983 |
| Enterprise Value/EBITDA | -7.63 |
Trading Information
MedinCell S.A. Stock Price History
| Beta (5Y Monthly) | 1.063009 |
| 52-Week Change | 26.97% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.5 EUR |
| 52 Week Low | 4.73 EUR |
| 50-Day Moving Average | 8.08 EUR |
| 200-Day Moving Average | 7.15 EUR |
MEDCL.PA Share Statistics
| Avg. Volume (3 month) | 81.87K EUR |
| Avg. Daily Volume (10-Days) | 53.67K EUR |
| Shares Outstanding | 28.69M |
| Float | 16.61M |
| Short Ratio | N/A |
| % Held by Insiders | 47.41% |
| % Held by Institutions | 19.18% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -325.25% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.53% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 8.52M EUR |
| Revenue Per Share (ttm) | 0.34 EUR |
| Quarterly Revenue Growth (yoy) | 276.19% |
| Gross Profit (ttm) | 4.09M EUR |
| EBITDA | -26769000 EUR |
| Net Income Avi to Common (ttm) | -26795000 EUR |
| Diluted EPS (ttm) | -1.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.15M EUR |
| Total Cash Per Share (mrq) | 0.56 EUR |
| Total Debt (mrq) | 48.46M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.203 |
| Book Value Per Share (mrq) | -1.039 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20031000 EUR |
| Levered Free Cash Flow (ttm) | -18198500 EUR |
Profile of MedinCell S.A.
| Country | France |
| State | N/A |
| City | Jacou |
| Address | 3 rue des FrEres LumiEre |
| ZIP | 34830 |
| Phone | 33 4 67 02 13 67 |
| Website | https://www.medincell.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 151 |
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Q&A For MedinCell S.A. Stock
What is a current MEDCL.PA stock price?
MedinCell S.A. MEDCL.PA stock price today per share is 9.17 EUR.
How to purchase MedinCell S.A. stock?
You can buy MEDCL.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MedinCell S.A.?
The stock symbol or ticker of MedinCell S.A. is MEDCL.PA.
Which industry does the MedinCell S.A. company belong to?
The MedinCell S.A. industry is Biotechnology.
How many shares does MedinCell S.A. have in circulation?
The max supply of MedinCell S.A. shares is 29.05M.
What is MedinCell S.A. Price to Earnings Ratio (PE Ratio)?
MedinCell S.A. PE Ratio is now.
What was MedinCell S.A. earnings per share over the trailing 12 months (TTM)?
MedinCell S.A. EPS is -1.01 EUR over the trailing 12 months.
Which sector does the MedinCell S.A. company belong to?
The MedinCell S.A. sector is Healthcare.